PerkinElmer (PKI) Earning Somewhat Favorable News Coverage, Accern Reports
News coverage about PerkinElmer (NYSE:PKI) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PerkinElmer earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.0122704546777 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- See what the IHS Markit Score report has to say about Perkinelmer Inc. (finance.yahoo.com)
- PerkinElmer, Inc. (United States) – Value Analysis (NYSE:PKI) : August 8, 2017 (finance.yahoo.com)
- PerkinElmer, Inc. (PKI) Price Target Raised to $74.00 at Citigroup Inc. (americanbankingnews.com)
- PerkinElmer, Inc. (PKI) Issues Earnings Results (americanbankingnews.com)
- PerkinElmer, Inc. (PKI) Earns “Buy” Rating from Piper Jaffray Companies (americanbankingnews.com)
PKI has been the topic of several recent analyst reports. BidaskClub cut shares of PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price target on the stock in a report on Wednesday, July 19th. Piper Jaffray Companies reiterated a “buy” rating and issued a $81.00 price target on shares of PerkinElmer in a report on Friday, August 4th. Citigroup Inc. lifted their price target on shares of PerkinElmer from $67.00 to $74.00 and gave the company a “buy” rating in a report on Monday. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $49.00 price target on shares of PerkinElmer in a report on Monday, May 15th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $67.00.
Shares of PerkinElmer (NYSE:PKI) traded up 1.56% during mid-day trading on Friday, hitting $63.93. 497,434 shares of the stock were exchanged. PerkinElmer has a 12 month low of $45.35 and a 12 month high of $70.16. The firm has a market cap of $7.05 billion, a P/E ratio of 19.28 and a beta of 0.75. The stock’s 50 day moving average is $67.37 and its 200 day moving average is $60.75.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The business had revenue of $547 million for the quarter, compared to the consensus estimate of $554.14 million. During the same quarter in the prior year, the company earned $0.67 EPS. The business’s revenue was up 2.0% compared to the same quarter last year. Analysts expect that PerkinElmer will post $2.89 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Thursday, October 19th. PerkinElmer’s payout ratio is 8.46%.
In other news, Director Peter Barrett sold 10,000 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $63.22, for a total transaction of $632,200.00. Following the transaction, the director now owns 29,200 shares of the company’s stock, valued at approximately $1,846,024. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Andrew Okun sold 4,358 shares of the stock in a transaction on Monday, June 19th. The stock was sold at an average price of $65.00, for a total value of $283,270.00. Following the transaction, the insider now directly owns 16,799 shares in the company, valued at approximately $1,091,935. The disclosure for this sale can be found here. Insiders have sold a total of 20,986 shares of company stock worth $1,330,317 in the last three months. Corporate insiders own 2.20% of the company’s stock.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.